Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
BörsenkürzelPLSE
Name des UnternehmensPulse Biosciences Inc
IPO-datumMay 18, 2016
CEOMr. Paul A. Laviolette
Anzahl der mitarbeiter75
WertpapierartOrdinary Share
GeschäftsjahresendeMay 18
Addresse3957 Point Eden Way
StadtHAYWARD
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94545
Telefon15109064600
Websitehttps://www.pulsebiosciences.com/
BörsenkürzelPLSE
IPO-datumMay 18, 2016
CEOMr. Paul A. Laviolette
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten